NOVAVAX INC Form 3 April 10, 2009

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB Number:

3235-0104

Expires:

January 31, 2005

0.5

Estimated average burden hours per

response...

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF **SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting

Person *

A Cadila Pharmaceuticals Ltd

(Last)

(First)

(Middle)

Statement

(Month/Day/Year)

03/31/2009

2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol

NOVAVAX INC [NVAX]

4. Relationship of Reporting Person(s) to Issuer

5. If Amendment, Date Original

Filed(Month/Day/Year)

CADILA CORPORATE CAMPUS, Â SARKHEJ -**DHOLKA ROAD**

(Street)

X 10% Owner Director Officer Other

(give title below) (specify below)

(Check all applicable)

6. Individual or Joint/Group

Filing(Check Applicable Line) Form filed by One Reporting

Person

X Form filed by More than One

Reporting Person

BHAT, AHMEDABAD GUJARAT, K7Â 382 210

(City)

(Instr. 4)

1. Title of Security

Common Stock

(State)

(Zip)

Table I - Non-Derivative Securities Beneficially Owned

2. Amount of Securities Beneficially Owned

(Instr. 4)

3. Ownership 4. Nature of Indirect Beneficial

Ownership Form: (Instr. 5)

Direct (D) or Indirect (I) (Instr. 5)

12,500,000 Ι See Footnote (1)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

4.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)

Expiration Date (Month/Day/Year)

2. Date Exercisable and 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)

5. Ownership Conversion or Exercise Form of

6. Nature of Indirect Beneficial Ownership

(Instr. 5)

Price of Derivative Derivative

Edgar Filing: NOVAVAX INC - Form 3

Date Expiration Title Amount or Security
Exercisable Date Number of Shares

or Indirect (I) (Instr. 5)

Direct (D)

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Cadila Pharmaceuticals Ltd CADILA CORPORATE CAMPUS SARKHEJ - DHOLKA ROAD BHAT, AHMEDABAD GUJARAT, K7 382 210	Â	ÂX	Â	Â
Satellite Overseas (Holdings) Ltd 7 HILL STREET, DOUGLAS ISLE OF MAN. E9 1M1EF	Â	ÂX	Â	Â

Signatures

/s/ Rajiv I. Modi, Managing
Director

**Signature of Reporting Person

By: /s/ Rajiv I.. Modi,
Director

**Signature of Reporting Person

Date

04/07/2009

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

These shares are owned directly by Satellite Overseas (Holdings) Limited, which is a wholly owned subsidiary (except for directors' qualifying shares) of Cadila Pharmaceuticals Ltd. Cadila Pharmaceuticals Ltd is an indirect beneficial owner of the reported securities. These shares are held for convenience in the name of "SOHL, Inc., as nominee for Satellite Overseas (Holdings) Limited." SOHL, Inc. has no voting, dispositive or pecuniary interest in any such shares.

Â

Remarks:

Exhibit List

Exhibit 99 - Joint Filer Information

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2